07.27.20

Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications

Source: Oculis

06.24.20

AsclepiX Therapeutics Announces $35 Million Series A Financing

Source: AsclepiX Therapeutics

05.29.20

Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for DME Drug Candidate

Source: Adverum Biotechnologies

05.07.20

Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery

Source: Oculis

02.10.20

Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)

Source: Oculis

02.10.20

Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseases

Source: Kodiak Sciences

02.10.20

Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DME

Source: Oxurion

01.23.20

Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for DR and DME from Apexian Pharmaceuticals

Source: Ocuphire Pharma

01.13.20

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases

Source: Exonate

01.07.20

Oxurion Reports Positive Topline Data From Phase 1 Study of THR-687 for Treatment of DME

Source: Oxurion

View more stories